




























![]()
Q1: 2026-05-05 Earnings Summary
EPS of $1.94 beats by $0.24
|
Revenue of
$814.50M
(42.25% Y/Y)
beats by $46.62M
Neurocrine Biosciences, Inc. (NBIX) Q1 2026 Earnings Call May 5, 2026 4:30 PM EDT
Company Participants
Todd Tushla - Vice President of Investor Relations
Kyle Gano - President, CEO & Director
Matthew Abernethy - Chief Financial Officer
Eric Benevich - Chief Commercial Officer
Sanjay Keswani - Chief Medical Officer
Conference Call Participants
Tazeen Ahmad - BofA Securities, Research Division
Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division
Brian Abrahams - RBC Capital Markets, Research Division
Cory Kasimov - Evercore ISI Institutional Equities, Research Division
Corinne Jenkins - Goldman Sachs Group, Inc., Research Division
Philip Nadeau - TD Cowen, Research Division
Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division
Anupam Rama - JPMorgan Chase & Co, Research Division
Jay Olson - Oppenheimer & Co. Inc., Research Division
Myles Minter - William Blair & Company L.L.C., Research Division
So Youn Shim - UBS Investment Bank, Research Division
Basma Radwan Ibrahim - Leerink Partners LLC, Research Division
Susan Chor - Wells Fargo Securities, LLC, Research Division
Poorna Kannan - Needham & Company, LLC, Research Division
David Amsellem - Piper Sandler & Co., Research Division
Yigal Nochomovitz - Citigroup Inc., Research Division
Sumant Kulkarni - Canaccord Genuity Corp., Research Division
Yatin Suneja - Guggenheim Securities, LLC, Research Division
Danielle Brill Bongero - Truist Securities, Inc., Research Division
Laura Chico - Wedbush Securities Inc., Research Division
Samuel Beck - Deutsche Bank AG, Research Division
Guofang Li - Wolfe Research, LLC
Malcolm Hoffman - BMO Capital Markets Equity Research
Presentation
Operator
Hello, and welcome, everyone joining today's Neurocrine Biosciences' Q1 2026 Earnings Call. [Operator Instructions] Please note, this call is being recorded. [Operator Instructions]
It is now my pleasure to turn the meeting over to Todd Tushla, Vice President of Investor Relations. Please go ahead.
Todd Tushla
Vice President of Investor Relations
Thank you, and happy Cinco de Mayo to everyone. Welcome to Neurocrine Biosciences' First Quarter 2026 Earnings Call. Joining me today are Kyle Gano, Chief Executive Officer; Matt Abernethy, Chief
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。